NTRA — Natera, Inc.
Is NTRA overbought or oversold? Here is the current MarketMoodz read.
Natera, Inc. (NTRA) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Diagnostics & Research) last closed at $288.48. The rating moved from Oversold to Strong Oversold on November 17, 2026.
- Public ratingStrong Oversold (as of November 17, 2026)
- Last close$288.48
- Last changeMoved from Oversold to Strong Oversold on November 17, 2026
- SectorHealthcare
- IndustryDiagnostics & Research
See all oversold Healthcare stocks →
AI analysis
Natera is positioned in attractive end markets (reproductive testing and oncology MRD) with recurring-revenue characteristics and strong clinical partnerships that support medium-term growth. Monitor upcoming clinical readouts, payer coverage decisions, and quarterly results for clearer directional catalysts.
Key factors
- Leading molecular diagnostics portfolio with growth exposure from oncology MRD (Signatera) and reproductive health (NIPT) franchises
- Recurring-revenue opportunity from longitudinal cancer surveillance and increasing clinical use cases that support durable revenue streams
- Partnerships with pharma and health systems that expand clinical validation and commercial adoption pathways
- Operational leverage potential as volume scales, which could improve gross margins and move the company toward profitability
- Current market environment (risk-on tone but rate uncertainty) reduces appetite for aggressive re-rating in near-term; valuation sensitivity to execution
- Exposure to payer/reimbursement dynamics and any changes in Medicare program integrity efforts that could affect collections or billing practices
Risks
- Reimbursement pressure and payer coverage restrictions for genetic and MRD tests; increased payor scrutiny or coding/audit actions could reduce realized revenues
- Regulatory and compliance risk including potential billing audits, RADV-style clawbacks or tighter Medicare/Medicaid program integrity enforcement
- Intense competition from other diagnostics and liquid‑biopsy players that can pressure pricing and market share
- Execution risk on commercial rollouts, scaling lab operations, and converting clinical validation into broad adoption
- Valuation and sentiment volatility: high-growth diagnostics stocks can reprice sharply on earnings misses or guidance cuts
- Possible need for additional capital if cash flow lags expectations, dilutive financing risk
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for NTRA — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.